Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mass., November 16, 2023-(BUSINESS WIRE)-Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products

for spine fusion markets, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of

1,139,063 of its shares of common stock at a purchase price of $0.64 per share in a registered direct offering priced at-the-market under

Nasdaq rules. In a concurrent private placement, the company has also agreed to issue and sell unregistered warrants to purchase up to

an aggregate of 1,139,063 shares of its common stock. The offering is expected to close on or about November 20, 2023, subject to the

satisfaction of customary closing conditions.

Wainwright & Co. is acting as the exclusive placement agent for the offering.

unregistered warrants will have an exercise price $0.52 per share, will become exercisable upon issuance and have a term of five and

one-half years from the date of issuance.

gross proceeds to Bone Biologics from the offering are expected to be approximately $729,200, before deducting the placement agent's

fees and other offering expenses payable by the Company. Bone Biologics currently intends to use the net proceeds from the offering to

fund clinical trials, maintain and extend its patent portfolio and for working capital and other general corporate purposes.

shares of common stock offered in the registered direct offering (but excluding the unregistered warrants offered in the concurrent private

placement and the shares of common stock underlying such unregistered warrants) are being offered and sold by the Company pursuant to

a "shelf" registration statement on Form S-3 (Registration No. 333-265872), including a base prospectus, previously filed

with the Securities and Exchange Commission (SEC) on June 28, 2022 and declared effective by the SEC on July 11, 2022. The offering of

the shares of common stock to be issued in the registered direct offering are being made only by means of a prospectus supplement that

forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered

direct offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic

copies of the final prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting H.C. Wainwright

& Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

offer and sale of the unregistered warrants in the private placement are being made in a transaction not involving a public offering

and have not been registered under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") and/or

Rule 506(b) of Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants,

have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered warrants offered

in the private placement and the underlying shares of common stock may not be offered or sold in the United States except pursuant to

an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable

state securities laws.

press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale

of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration

or qualification under the securities laws of any such state or jurisdiction.

Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds

on the preclinical research of the Nell-1 protein. Bone Biologics is currently focusing its development efforts for its bone graft substitute

product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For

more information, please visit www.bonebiologics.com.

statements contained in this press release, including, without limitation, statements regarding the completion of the offering, the satisfaction

of customary closing conditions related to the offering and the anticipated use of proceeds therefrom, as well as statements containing

the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking

statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve

both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its

forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and those including

the Company's ability to develop our lead product NELL-1 and other proposed products, its ability to obtain patent protection for

its technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability

to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other

regulatory approval necessary to market any product in other countries, its ability to market any product it may develop, its ability

to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business

strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic

and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under

"Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations"

in the Company's Form S-1, Form 10-K for the year ended December 31, 2022 and the Company's other filings with the Securities

and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements

to reflect any event or circumstance that may arise after the date hereof.